Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

Multilingual Wikipedia

In June 2020 the work Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma was on the 804,128th place in the ranking of the most reliable and popular publications with DOI number in multilingual Wikipedia from readers' point of view (PR-score). If we consider only frequency of appearance of this source in references of Wikipedia articles (F-score), this work was on the 975,286th place in June 2020. From Wikipedians' point of view, "Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma" is the 725,878th most reliable publication with DOI number in different language versions of Wikipedia (AR-score).

PR-score:
804,128th place
884
-777
AR-score:
725,878th place
223
+8
F-score:
975,286th place
1
0

English Wikipedia (en)

PR-score:
677,403rd place
884
-777
AR-score:
606,232nd place
223
+8
F-score:
806,882nd place
1
0

BestRef shows popularity and reliability scores for sources in references of Wikipedia articles in different languages. Data extraction based on complex method using Wikimedia dumps. To find the most popular and reliable sources we used information about over 200 million references of Wikipedia articles. More details...